NIH's Healy Has To Play The Numbers Game

National Institutes of Health director Bernadine Healy says she is trying to shift the debate over adequate funding for biomedical research away from scientists and toward health as she sells the idea of a larger NIH budget to Congress and the public. But sometimes it's hard to separate the needs of her colleagues and the needs of the country. "I'm not talking about a full-employment program for scientists," she told a recent meeting of the director's advisory committee that was focusing on

Written byJeffrey Mervis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

"I'm not talking about a full-employment program for scientists," she told a recent meeting of the director's advisory committee that was focusing on the issue of indirect costs. "What we need to remember is that our goals are to fight disease and promote good health. That's what Congress gives us money to do."

But in the past several years, supporters of NIH have used the number of new grants to individual investigators as a barometer for the overall health of the NIH budget. They managed to push that number up to a record 6,440 in 1987, before it plunged to 4,840 in 1990. Although this year it is expected to once again top 6,000, Healy told the advisory board she no longer believes that it is an important target.

"We are not obsessed by the number of grants, either new or in toto," she said. "We are more concerned with ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies